This finding suggested that the antidepressant-like profile seems to involve the serotonergic system as underlying mechanism.”
“A group of N-phenylacetamide, N-phenylpropanamide and N-benzylamide derivatives bearing 5-membered heterocyclic rings such as pyrazole, 1,2,4-triazole and imidazole rings at omega position were synthesized and their anticonvulsant activity was evaluated

in the maximal electroshock test. The results indicated that the 1,2,4-triazole ring leads to superior activity than the pyrazole ring and inserting a CH(2) group into the anilide structure leading to N-benzyl derivatives did not change the anticonvulsant activity, but caused a noticeable decrease in duration of action. The most active compound was 2-(1H-1,2,4-triazole-1-y1)-N(2,6-dimethylphenyl)acetamide.”
“A sensitive and selective high performance liquid chromatographic (HPLC) method was developed www.selleckchem.com/products/gsk923295.html and validated for estimation of lamotrigine (CAS 84057-84-1) in human plasma and saliva. The chromatographic separation was achieved with a reversed phase column and a mobile phase consisting of acetonitrile and 20 mM ammonium acetate buffer pH 6.5 (30:70) with a flow rate of 1 mL/min. The calibration curve was linear within the working range for both plasma and saliva. The validated method has been successfully applied for a study of lamotrigine in human plasma and

saliva to establish the correlation between these two matrices. A scatter plot AG-881 of plasma click here versus salivary lamotrigine concentrations showed a good linear relationship between them (Pearson correlation coefficient, r = 0.6832, p < 0.001).”
“Background

and objective: The purpose of the present study was to compare the bioavailability of a new methyldopa (CAS 555-30-6) tablet formulation with that of a reference formulation in 12 healthy male subjects using a modified HPLC method.

Methods: The study was designed as an open label, single-dose, randomized study with a cross-over design. Under fasting conditions, each subject received one 250-mg tablet orally as a single dose of a test or reference formulation on two treatment days. The treatment periods were separated by a one-week washout period. The blood samples were collected at different time points after each administration and determined using a rapid and reliable modified HPLC method. The method used was validated for specificity, accuracy, precision and sensitivity. The pharmacokinetic parameters (C(max), AUC(0-t), AUC(0-infinity)) were statistically compared by analysis of variance (ANOVA) for test and reference formulations.

Results and discussion: All validation criteria for the developed HPLC method were in acceptable range. The maximum plasma concentration (C(max)) of alpha-methyldopa was 270.3-1864.9 ng/ml for the test and 224.5-1585.6 ng/ml for the reference formulation. The mean AUC(0-infinity) of alpha-methyldopa was 2002.1-10614.8 and 2076.8-9056.